Real-time analyst ratings, insider transactions, earnings data, and more. Viridian Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Viridian Therapeutics Inc 52 week low is $9.47 as of April 29, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Viridian Therapeutics Inc 52 week high is $39.00 as of April 29, 2023. We’d like to share more about how we work and what drives our day-to-day business.

The 50-is it better to cancel unused credit cards or keep moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Viridian Therapeutics Inc 50-day moving average is $28.52. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 11 Wall Street equities research analysts have issued «buy,» «hold,» and «sell» ratings for Viridian Therapeutics in the last year. The consensus among Wall Street equities research analysts is that investors should «buy» VRDN shares. 11 Wall Street research analysts have issued 1-year price objectives for Viridian Therapeutics’ shares. Their VRDN share price forecasts range from $40.00 to $51.00.

Viridian Therapeutics stock price target raised to $40 from $25 at B. Riley

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.

There may be delays, omissions, or inaccuracies in the Information. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.

Recently Viewed Tickers

Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Viridian Therapeutics’ stock was trading at $29.21 on January 1st, 2023. Since then, VRDN stock has decreased by 4.0% and is now trading at $28.03. The P/E ratio of Viridian Therapeutics is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 8.28% of the outstanding shares of Viridian Therapeutics have been sold short. According to analysts’ consensus price target of $45.67, Viridian Therapeutics has a forecasted upside of 62.9% from its current price of $28.03.

It can also be calculated by dividing the company’s Market Cap by the Net Profit. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

«Prepare for Five Years of Famine»Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast. Viridian Therapeutics does not have a long track record of dividend growth. Short interest in Viridian Therapeutics has recently increased by 2.90%, indicating that investor sentiment is decreasing.

Viridian Therapeutics, Inc

On average, they predict the company’s share price to reach $45.67 in the next year. This suggests a possible upside of 62.9% from the stock’s current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts. Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.

The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA. According to 9 analysts, the average rating for VRDN stock is «Strong Buy.» The 12-month stock price forecast is $42.56, which is an increase of 51.84% from the latest price. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share .

JMP Securities Remains a Buy on Viridian Therapeutics (VRDN)

This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies. Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics.

It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts. Market cap, also known as market capitalization, is the total market value of a company.

Analyst Ratings

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.

These are established companies that reliably pay dividends. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Viridian Therapeutics has a news sentiment score of 0.93.

In the past three months, Viridian Therapeutics insiders have sold 935.60% more of their company’s stock than they have bought. Specifically, they have bought $261,805.00 in company stock and sold $2,711,257.00 in company stock. Viridian Therapeutics has a short interest ratio («days to cover») of 6.7. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Viridian Therapeutics, Inc. delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Viridian Therapeutics, Inc. delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022.

Intraday data delayed at least 15 minutes or per exchange requirements. Represents the company’s profit divided by the outstanding shares of its common stock. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

• MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
• Viridian Therapeutics does not have a long track record of dividend growth.
• One share of VRDN stock can currently be purchased for approximately $28.03.
• Intraday data delayed at least 15 minutes or per exchange requirements.
• The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.
• Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

Our https://1investing.in/ management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Viridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The technique has proven to be very useful for finding positive surprises.

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

It’s calculated by multiplying the current market price by the total number of shares outstanding. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody being developed for the potential treatment for patients with thyroid eye disease.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareVRDN’s historical performanceagainst its industry peers and the overall market. One share of VRDN stock can currently be purchased for approximately $28.03. Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.